irr

OSI-906 (Linsitinib (OSI-906)) is an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.

AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).

AZ7550 hydrochloride (AZ7550 hydrochloride ), an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).

AZ7550 trimesylate salt (AZ7550 Mesylate) is the active metabolite of ositinib, AZ7550 trimesylate salt inhibits IGF1R activity and can be used in the study of non-small cell lung cancer.

SirReal1-O-propargyl, a moiety based on SirReal1, is a selective and highly potent inhibitor of Sirtuin 2 (Sirt2), demonstrating an IC50 of 2.4 μM. It operates by binding to the cereblon ligand through a linker, facilitating the formation of PROTAC for the degradation of Sirt2[1].

SirReal-1 is an effective and selective inhibitor of Sirt2.

Kirromycin is an antibiotic originally isolated from Streptomyces and an inhibitor of protein biosynthesis. It inhibits isoleucine incorporation, polyphenylalanine synthesis, and growth of B. brevis. Kirromycin inhibits elongation factor Tu-dependent peptidyl transfer activity in E. coli.

SirReal2 is a potent and selective Sirt2 inhibitor with IC50 of 140 nM.

Cirramycin A1 exhibits activity against both Gram-positive and Gram-negative bacteria and is also effective against various mycoplasmas. Its minimum inhibitory concentration against Mycoplasma pneumoniae is 0.001 μg/mL.

Cirramycin B1 exhibits activity against both Gram-positive bacteria, Gram-negative bacteria, and mycoplasmas.

Kirrothricin exhibits antibacterial properties, but it is inactive against Bacillus subtilis, Escherichia coli, and fungi.